Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ)

$24.99

Current Ratio
since 2005

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Johnson & Johnson, current ratio, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in millions


The financial data reveals several notable trends in the liquidity position over the analyzed periods. The current assets demonstrate variability, with an initial decline from 31,394 million USD at the end of 2005 to a low of 22,975 million USD in 2006, followed by a general upward movement until 2011, peaking at 54,316 million USD. However, a sharp decrease is observed in 2017, where current assets dropped to 43,088 million USD from 65,032 million USD in 2016. After this dip, the assets once again exhibit a rising trend up to 2021, reaching 60,979 million USD, before fluctuating downward through 2024.

Current liabilities present a general upward trajectory throughout the years, starting at 12,635 million USD in 2005 and escalating consistently to reach a peak of 55,802 million USD in 2022. Minor declines appear in 2014 and 2016, but these are temporary as the overall trend remains increasing, indicative of growing obligations over time.

The current ratio, which reflects liquidity by comparing current assets to current liabilities, shows significant fluctuations and an overall declining tendency in recent years. Initially, the ratio is relatively high at 2.48 in 2005, followed by a steep drop to 1.2 in 2006. From then, it gradually recovers to a high of 2.47 in 2016. Post-2016, there is a marked decline, falling below the critical threshold of 1 in 2022 (0.99), before modestly increasing again but remaining near or just above 1 through 2024. This pattern suggests a weakening short-term liquidity position towards the latter part of the period.

Current Assets
Exhibit an overall increasing trend from 2006 to 2011, a sharp decline in 2017, followed by recovery and fluctuation through 2024.
Current Liabilities
Show a consistent upward trend across the entire period, indicating rising short-term obligations.
Current Ratio
Starts high, falls sharply in 2006, recovers until 2016, then declines again, dipping below 1 in 2022, signaling potential liquidity challenges in recent years.

Comparison to Competitors

Johnson & Johnson, current ratio, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Johnson & Johnson, current ratio, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)